Den europeiske union - norsk - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfat - abdominal neoplasmer - antineoplastiske midler - vitrakvi som monoterapi er indisert for behandling av voksne og paediatric pasienter med solide svulster som viser en neurotrophic reseptor tyrosin kinase (ntrk) - genet fusion,som har en sykdom som er lokalt avansert eller metastatisk hvor kirurgisk reseksjon er sannsynlig å resultere i alvorlig sykelighet, andwho har ingen tilfredsstillende behandlingstilbud.

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.